A Randomised comparison of anastrozole commenced before and continuing during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy.

This study compares the effectiveness of treatment with the drug anastrozole before and during adjuvant radiotherapy compared with anastrozole therapy delayed until after radiotherapy. This study is for woman who have had a mastectomy or lumpectomy for breast cancer, and all planned surgery is now complete and radiotherapy is recommended. Participants will be divided into two groups. One group will receive anastrozole orally before and during radiotherapy. The other group will receive standard treatment, where anastrozole and subsequent anti-oestrogen therapy is delayed until after radiotherapy. Participants will be monitored for 10 years after radiotherapy. The study aims to determine if commencement of anastrozole before radiotherapy results in improved local control of the disease.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

2023

Closing Date of Accrual

November 2016

Trial Chairperson

Prof Peter Graham, St George Clinical Trials Unit, St George Hospital, NSW

Trial Contact

SESLHD-STARStrial@health.nsw.gov.au

Clinical Trial Registration

Related Post

World Radiotherapy Awareness Day promotion at ESTRO26
10 June, 2026

Global cancer community prepares to unite for 2026 World Radiotherapy Awareness Day

LATEST NEWS: 10 June 2026 The global radiation therapy

4 June, 2026

Report showcases a year of impactful research, collaboration and consumer engagement

LATEST NEWS: 4 June 2025 TROG’s latest Annual Research